|
2026
|
P/S
|
Pharmaceutical and biological preparations for treating
tenosynovial giant cell tumor (TGCT), gi... |
|
|
Invention
|
Methods of treating disorders using csf1r inhibitors.
Described herein are methods of treating c... |
|
|
Invention
|
Formulations of vimseltinib.
Described herein, in part, are pharmaceutically acceptable formulat... |
|
|
Invention
|
Cdk inhibitors and methods of use thereof. Described herein are compounds that are inhibitors of ... |
|
2025
|
Invention
|
Formulations of ulk inhibitors. Described herein, in part, are pharmaceutically acceptable formul... |
|
|
Invention
|
Solid state forms of a kinase inhibitor. Described herein, in part, are solid-state forms of the ... |
|
|
Invention
|
Dual raf and tubulin inhibitors and methods of use thereof.
Described herein are compounds that ... |
|
|
Invention
|
Csf-1r inhibitors and methods of use thereof. Provided herein, in part, is a compound of Formula ... |
|
|
Invention
|
Gcn2 and perk kinase modulators and methods of use thereof.
Described herein are compounds that ... |
|
|
Invention
|
Methods of treating disorders using csfir inhibitors. Described herein are methods of treating ca... |
|
|
Invention
|
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof.
Described herei... |
|
|
Invention
|
Solid state forms of a ulk inhibitor. Provided herein, in part, are solid-state salt forms of the... |
|
|
Invention
|
Solid state forms of ulk inhibitors. Provided herein, in part, are solid-state forms of the compo... |
|
|
Invention
|
Amorphous kinase inhibitor formulations and methods of use thereof.
Provided herein is an amorph... |
|
|
Invention
|
Solid state forms of ripretinib.
The present disclosure relates to solid state forms of ripretin... |
|
|
Invention
|
Processes of making csf-1r inhibitors and methods of use thereof. The present disclosure relates ... |
|
|
Invention
|
Formulations of vimseltinib. Described herein, in part, are pharmaceutically acceptable formulati... |
|
|
P/S
|
Pharmaceutical oncology treatments, namely, preparations for
gastrointestinal stromal tumors, sy... |
|
|
P/S
|
downloadable mobile application for use by patients to manage, track, and generate reports on med... |
|
|
P/S
|
Provision of consumer information regarding the selection of prescription medications to be purch... |
|
|
Invention
|
Aminopyrimidine amide autophagy inhibitors and methods of use thereof.
Described herein are comp... |
|
|
Invention
|
Methods of treating gastrointestinal stromal tumors.
The present disclosure relates to methods o... |
|
|
Invention
|
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-... |
|
|
Invention
|
Methods of treating tenosynovial giant cell tumors.
The present disclosure provides, inter alia,... |
|
|
Invention
|
Methods of treating disorders using csf1r inhibitors. Described herein are methods of treating ca... |
|
|
Invention
|
Ulk inhibitors and methods of use thereof. Described herein are compounds of formula (I) that are... |
|
|
P/S
|
Pharmaceutical preparations and biological materials for treating tenosynovial giant cell tumor (... |
|
2024
|
Invention
|
Raf kinase inhibitors and methods of use thereof.
Described herein are compounds that are RAF in... |
|
|
Invention
|
Dual raf and tubulin inhibitors and methods of use thereof |
|
|
Invention
|
Dual raf and tubulin inhibitors and methods of use thereof. Described herein are compounds of for... |
|
|
Invention
|
Vps34 inhibitors and methods of use thereof.
The present disclosure, in part, provide compounds ... |
|
|
Invention
|
Vps34 inhibitors and methods of use thereof. The present disclosure, in part, provide compounds o... |
|
|
Invention
|
Formulations of a csf-1r inhibitor. Described herein, in part, are pharmaceutically acceptable fo... |
|
|
Invention
|
Formulations of a csf-1r inhibitor.
Described herein, in part, are pharmaceutically acceptable f... |
|
|
Invention
|
Solid forms of an ulk inhibitor.
Described herein, in part, are solid-state forms of the compoun... |
|
|
Invention
|
Solid state forms of a kinase inhibitor |
|
|
Invention
|
Formulations of vimseltinib |
|
|
Invention
|
Methods of treating tenosynovial giant cell tumors |
|
|
P/S
|
Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for use in... |
|
|
P/S
|
Pharmaceutical and biological preparations for treating tenosynovial giant cell tumor (TGCT), gia... |
|
2023
|
P/S
|
pharmaceutical oncology treatments, namely, preparations for gastrointestinal stromal tumors, sys... |
|
|
P/S
|
Pharmaceutical oncology treatments, namely, preparations for gastrointestinal stromal tumors, sys... |
|
2021
|
P/S
|
Business administration of patient reimbursement programs; business administration of medication ... |
|
|
P/S
|
pharmaceutical research and development providing medical information to patients relating to the... |
|
2019
|
P/S
|
Pharmaceutical oncology treatments, namely treatments for gastrointestinal stromal tumors, system... |
|
|
P/S
|
Pharmaceutical oncology treatments, namely preparations for treating gastrointestinal stromal tum... |
|
2017
|
Invention
|
Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophe... |
